Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series
Clinical Journal of Gastroenterology · 2024
DOI: 10.1007/s12328-024-01946-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Koki Sakaguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Three patients aged 79, 75, and 81 years with unresectable hepatocellular carcinoma (HCC) and undergoing maintenance hemodialysis were treated with a combination of atezolizumab and bevacizumab. The patients, respectively, received their 22nd, 2nd, and 4th treatment cycles, and one achieved long-term stable disease. No serious adverse events, including immune-related adverse events, were observed in any patient. Remarkable progress has been made in chemotherapy for cancer; however, the efficacy and safety of chemotherapy in patients undergoing hemodialysis have not been adequately elucidated. This report provides novel insights into the feasibility and outcomes of atezolizumab and bevacizumab combination therapy in patients with HCC undergoing hemodialysis, highlighting its potential as a viable treatment option with manageable side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan.
- Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan. tatsunori-sato@i.shizuoka-pho.jp.
- Department of Gastroenterology, Yaizu City Hospital, Shizuoka, Japan.
- Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Zitieren
APA
Sakaguchi, K., Satoh, T., Kawaguchi, S., Aoyama, T., Asahara, K., Endo, S., Shirane, N., Kanemoto, H., Oba, N., & Ohno, K. (2024). Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-01946-7
Vancouver
Sakaguchi K, Satoh T, Kawaguchi S, Aoyama T, Asahara K, Endo S, et al. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-01946-7
BibTeX
@article{Sakaguchi2024,
author = {Sakaguchi, Koki and Satoh, Tatsunori and Kawaguchi, Shinya and Aoyama, Takuya and Asahara, Kazuhisa and Endo, Shinya and Shirane, Naofumi and Kanemoto, Hideyuki and Oba, Noriyuki and Ohno, Kazuya},
title = {Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series},
journal = {Clinical Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s12328-024-01946-7}
}
EUVIMED